Research
Lingering CAR T cells may be the cause of serious gut complication after myeloma therapy
The Brief
- Patients with multiple myeloma who developed a serious gastrointestinal side effect after CAR T cell therapy had significantly more CAR T cells persisting in their bloodstream.
- The findings come from new research from The University of Texas MD Anderson Cancer Center.
Why it matters
It suggests that prolonged persistence of CAR T cells may be linked to serious gut complications after myeloma treatment, which could inform how these patients are monitored.
Who’s affected
- clinicians treating multiple myeloma patients with CAR T cell therapy
- patients receiving or considering CAR T cell therapy for multiple myeloma
- #car t cells
- #multiple myeloma
- #immunotherapy
- #gastrointestinal side effects
- #cancer research
Patients with multiple myeloma who developed a serious gastrointestinal side effect after treatment with chimeric antigen receptor (CAR) T cell therapy had significantly more CAR T cells persisting in their bloodstream, according to new research from The University of Texas MD…